BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25768704)

  • 1. Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold.
    Zhao F; Liu N; Zhan P; Jiang X; Liu X
    Eur J Med Chem; 2015 Apr; 94():218-28. PubMed ID: 25768704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
    Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase.
    LaPorte MG; Draper TL; Miller LE; Blackledge CW; Leister LK; Amparo E; Hussey AR; Young DC; Chunduru SK; Benetatos CA; Rhodes G; Gopalsamy A; Herbertz T; Burns CJ; Condon SM
    Bioorg Med Chem Lett; 2010 May; 20(9):2968-73. PubMed ID: 20347591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.
    Beaulieu PL; Bös M; Bousquet Y; Fazal G; Gauthier J; Gillard J; Goulet S; LaPlante S; Poupart MA; Lefebvre S; McKercher G; Pellerin C; Austel V; Kukolj G
    Bioorg Med Chem Lett; 2004 Jan; 14(1):119-24. PubMed ID: 14684311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
    Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
    J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.
    Beaulieu PL; Gillard J; Jolicoeur E; Duan J; Garneau M; Kukolj G; Poupart MA
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3658-63. PubMed ID: 21550240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.
    Beaulieu PL; Gillard J; Bykowski D; Brochu C; Dansereau N; Duceppe JS; Haché B; Jakalian A; Lagacé L; LaPlante S; McKercher G; Moreau E; Perreault S; Stammers T; Thauvette L; Warrington J; Kukolj G
    Bioorg Med Chem Lett; 2006 Oct; 16(19):4987-93. PubMed ID: 16908138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.
    Goulet S; Poupart MA; Gillard J; Poirier M; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2010 Jan; 20(1):196-200. PubMed ID: 19945870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.
    Gopalsamy A; Lim K; Ciszewski G; Park K; Ellingboe JW; Bloom J; Insaf S; Upeslacis J; Mansour TS; Krishnamurthy G; Damarla M; Pyatski Y; Ho D; Howe AY; Orlowski M; Feld B; O'Connell J
    J Med Chem; 2004 Dec; 47(26):6603-8. PubMed ID: 15588095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D- QSAR and molecular docking studies.
    Cao H; Cao R; Zhang H; Zheng X; Gao D
    Curr Med Chem; 2008; 15(15):1462-77. PubMed ID: 18537623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
    Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
    Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.
    Harper S; Avolio S; Pacini B; Di Filippo M; Altamura S; Tomei L; Paonessa G; Di Marco S; Carfi A; Giuliano C; Padron J; Bonelli F; Migliaccio G; De Francesco R; Laufer R; Rowley M; Narjes F
    J Med Chem; 2005 Jul; 48(14):4547-57. PubMed ID: 15999993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finger loop inhibitors of the HCV NS5B polymerase: discovery and prospects for new HCV therapy.
    Beaulieu PL
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):618-26. PubMed ID: 17002222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
    Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
    J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.
    McGowan D; Vendeville S; Lin TI; Tahri A; Hu L; Cummings MD; Amssoms K; Berke JM; Canard M; Cleiren E; Dehertogh P; Last S; Fransen E; Van Der Helm E; Van den Steen I; Vijgen L; Rouan MC; Fanning G; Nyanguile O; Van Emelen K; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4431-6. PubMed ID: 22542193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor.
    Paparin JL; Amador A; Badaroux E; Bot S; Caillet C; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Giulia Loi A; McCarville J; Mascia V; Milhau J; Onidi L; Pierra C; Rahali R; Rosinosky E; Sais E; Seifer M; Surleraux D; Standring D; Dousson CB
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2634-2640. PubMed ID: 28416131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency.
    Beaulieu PL; Bös M; Bousquet Y; DeRoy P; Fazal G; Gauthier J; Gillard J; Goulet S; McKercher G; Poupart MA; Valois S; Kukolj G
    Bioorg Med Chem Lett; 2004 Feb; 14(4):967-71. PubMed ID: 15013003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors.
    Ontoria JM; Rydberg EH; Di Marco S; Tomei L; Attenni B; Malancona S; Martin Hernando JI; Gennari N; Koch U; Narjes F; Rowley M; Summa V; Carroll SS; Olsen DB; De Francesco R; Altamura S; Migliaccio G; Carfì A
    J Med Chem; 2009 Aug; 52(16):5217-27. PubMed ID: 19877603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.